Table 1.
Demographic and clinical data of the study population
| Recruited sample | Microarray Sample | Statistical Test | p-value | |
|---|---|---|---|---|
| Patients, N | 21 | 16 | ||
| Gender, male, N (%) | 2 (10.5%) | 0 (0%) | _ | _ |
| Age, years (mean ± SD) | 14.9 ± 1.5 | 14.9 ± 1.5 | U=165.5 | 0.952 |
| Diagnosis, N (%) | _ | _ | ||
| MDD | 19 (90.5%) | 16 (100%) | _ | _ |
| OCD | 1 (4.8%) | 0 (0%) | _ | _ |
| GAD | 1 (4.8%) | 0 (0%) | _ | _ |
| Comedication, N (%) | ||||
| Antipsychotics | 3 (14.29%) | 0 (0%) | _ | _ |
| Benzodiazepines | 5 (23.8%) | 5 (31.25%) | _ | _ |
| Baseline, score (mean ± SD) | ||||
| GAF/CGAS | 44.8 ± 9.2 | 45.38 ± 8.14 | U=162.0 | 0.865 |
| CGI-S | 4.5 ± 0.8 | 4.38 ± 0.62 | U=162.5 | 0.881 |
| CDI | 27.1 ± 11 | 29.2 ± 8.6 | t=-0.613 | 0.272 |
| OCI-CV | 15.0 ± 8.2 | 15.75 ± 7.9 | t=-0.295 | 0.384 |
| SCARED | 34.2 ± 14.8 | 38 ± 12.7 | t=-0.823 | 0.208 |
| 8 weeks, score (mean ± SD) | ||||
| GAF/CGAS | 55.7 ± 12.6 | 56.6 ± 13.6 | U=141.5 | 0.741 |
| CGI-S | 3.7 ± 0.9 | 3.6 ± 11.8 | U=144.5 | 0.818 |
| CDI | 23.6 ± 13.2 | 24.7 ± 11.8 | t=-0.794 | 0.219 |
| OCI-CV | 16.3 ± 9.8 | 16.8 ± 10.2 | t=-0.146 | 0.442 |
| SCARED | 34.1 ± 15.7 | 35.8 ± 15.3 | t=-0.324 | 0.756 |
| Fluoxetine 8 weeks, ng/mL (mean ± SD) | 123.68 ± 71.3 | 121.81 ± 71.92 | t=0.078 | 0.469 |
| Norfluoxetine 8 weeks, ng/mL (mean ± SD) | 154.63 ± 74.02 | 159.88 ± 73.32 | t=-0.207 | 0.418 |
| FLU+NORFLU 8 weeks, ng/mL (mean ± SD) | 278.31 ± 113.997 | 281.69 ± 110.62 | t=-0.086 | 0.466 |